Future therapies in Parkinson's disease may substantially build on the existence of intra‐
membrane receptor–receptor interactions in DA receptor containing heteromeric receptor …

Parkinson's disease and drug-induced movement disorders (DIMDs) have commonalities in
etiology based on impaired dopamine-based neurotransmission. Adenosine A 2A-receptor …

The A2A receptor has recently attracted considerable interest as a potential target for
Parkinson's disease (PD) therapy based on the motor-enhancing and neuroprotective …

Although levodopa remains the most effective drug for the symptomatic treatment of
Parkinson's disease, chronic therapy with this pharmacological compound initiates a …

Adenosine A2A receptors have a unique cellular and regional distribution in the basal
ganglia, being particularly concentrated in areas richly innervated by dopamine such as the …

Dyskinesia, a major complication of treatment of Parkinson's disease (PD), involves two
phases: induction, which is responsible for dyskinesia onset, and expression, which …

In Parkinson's disease a degeneration of dopaminergic neurons of the nigrostriatal pathway
is observed. Loss of dopaminergic regulation of striatal neuron activity results in altered …

Dual probe microdialysis was used to study A2A/D2 receptor interactions in the striato-
pallidal GABA pathway in a model of Parkinson's Disease. The A2A agonist CGS21680 …

Adenosine A2A receptors present in the central nervous system have been implicated in the
modulation of motor functions. Accordingly, adenosine A2A receptor antagonists currently …

Brain adenosine A2A receptors have recently attracted considerable attention because of
their interaction with the dopaminergic system and as potential targets for Parkinson's …